Immunocore Aims For $100m IPO After Immunotherapy Success

Proof-Of-Concept For TCR platform

 
• By Andrew McConaghie

The UK biotech is set for a NASDAQ launch which could propel it to its first commercial launch by 2022.

Nasdaq ipo
The UK-headquartered biotech is set to debut on the NASDAQ exchange shortly.

More from Archive

More from Scrip